Zum Inhalt springen

Scrip: Atriva: Targeting Patients, Not Virus, Is The Way Forward In Flu

  • 1 min read

John Davis – 27 Feb 2019 – ANALYSIS – Read the full article here

Executive Summary

Emerging Company Profile: Four-year-old Atriva Therapeutics GmbH is developing a drug to prevent the proliferation of flu virus by transiently inhibiting one of the patient’s own cellular processes, a host-mediated novel mechanism of action that could be effective against a range of respiratory virus infections.